These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma]. Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932 [TBL] [Abstract][Full Text] [Related]
8. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; Goldman JM; Apperley JF; Marin D Br J Haematol; 2008 May; 141(5):745-7. PubMed ID: 18331365 [No Abstract] [Full Text] [Related]
9. Double-edged sword of the new cancer therapeutics. Force T Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582 [No Abstract] [Full Text] [Related]
10. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review]. Liu B; Wang Y; Mi Y; Wang J Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596 [TBL] [Abstract][Full Text] [Related]
11. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Wang HC; Lee CS; Liu TC Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241 [No Abstract] [Full Text] [Related]
12. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. Tyler T Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654 [TBL] [Abstract][Full Text] [Related]
13. Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. Breccia M; Serrao A; Salaroli A; Loglisci G; Zacheo I; Alimena G Br J Haematol; 2012 Dec; 159(5):612-3. PubMed ID: 23043319 [No Abstract] [Full Text] [Related]
14. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844 [TBL] [Abstract][Full Text] [Related]
15. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412 [TBL] [Abstract][Full Text] [Related]
16. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase]. Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544 [TBL] [Abstract][Full Text] [Related]
18. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]. Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160 [TBL] [Abstract][Full Text] [Related]
19. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Shayani S Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900 [TBL] [Abstract][Full Text] [Related]